{
    "ticker": "CLGN",
    "name": "Calithera Biosciences, Inc.",
    "description": "Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics to treat cancer. Founded in 2010, the company is committed to advancing precision medicine through innovative approaches that target critical pathways in tumor growth and immune evasion. Calithera's lead product candidate, CB-839, is a first-in-class, oral inhibitor of the enzyme glutaminase, which is being evaluated in various clinical trials for the treatment of solid tumors. The company is also exploring the potential of its therapies in combination with existing treatments to enhance their effectiveness. With a robust pipeline of drug candidates and a dedicated research team, Calithera aims to provide new treatment options for patients suffering from cancer. The company's strategic collaborations with leading research institutions and biopharmaceutical companies reflect its commitment to advancing cancer care and improving patient outcomes. Additionally, Calithera's focus on understanding the tumor microenvironment and immune system interactions positions it at the forefront of innovative cancer research.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2010",
    "website": "https://www.calithera.com",
    "ceo": "Susan M. Molineaux",
    "social_media": {
        "twitter": "https://twitter.com/Calithera",
        "linkedin": "https://www.linkedin.com/company/calithera-biosciences/"
    },
    "investor_relations": "https://investors.calithera.com",
    "key_executives": [
        {
            "name": "Susan M. Molineaux",
            "position": "CEO"
        },
        {
            "name": "David L. O'Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Product Candidates",
            "products": [
                "CB-839"
            ]
        }
    ],
    "seo": {
        "meta_title": "Calithera Biosciences, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Calithera Biosciences, Inc., a leader in developing innovative therapeutic solutions for cancer treatment. Learn about our pipeline and commitment to precision medicine.",
        "keywords": [
            "Calithera",
            "Cancer Therapy",
            "Biopharmaceutical",
            "Precision Medicine",
            "CB-839"
        ]
    },
    "faq": [
        {
            "question": "What is Calithera Biosciences known for?",
            "answer": "Calithera Biosciences is known for its innovative cancer therapies, particularly its lead product candidate CB-839."
        },
        {
            "question": "Who is the CEO of Calithera Biosciences?",
            "answer": "Susan M. Molineaux is the CEO of Calithera Biosciences, Inc."
        },
        {
            "question": "Where is Calithera Biosciences headquartered?",
            "answer": "Calithera Biosciences is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Calithera's main product candidates?",
            "answer": "Calithera's main product candidate is CB-839, an oral inhibitor of glutaminase."
        },
        {
            "question": "When was Calithera Biosciences founded?",
            "answer": "Calithera Biosciences was founded in 2010."
        }
    ],
    "competitors": [
        "NVS",
        "AMGN",
        "BMY"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "REGN",
        "ABBV"
    ]
}